Rasburicase for Hyperuricemia

Summary

Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration. Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.

Timeline

Start

2005-06

Primary completion

2006-04

Completion

2006-04

Drugs

Indications